{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:34:14Z","timestamp":1789950854933,"version":"4.0.1"},"reference-count":113,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.012","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T15:21:59Z","timestamp":1704727319000},"page":"461-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Clonal Heterogeneity in Multiple Myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Carolina","family":"Schinke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2023.12.012_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.012_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.hoc.2023.12.012_bib3","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/asheducation-2010.1.303","article-title":"Relapsed Multiple Myeloma","volume":"2010","author":"Lonial","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.012_bib5","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.21.01987","article-title":"In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations","volume":"41","author":"Lannes","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.012_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","article-title":"Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing","volume":"27","author":"Cohen","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A\u00a0high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.012_bib8","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.012_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.012_bib11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2023.12.012_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","author":"Rasche","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.012_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib15","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.012_bib16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A\u00a0novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.012_bib17","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3324\/haematol.2009.016329","article-title":"The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance","volume":"95","author":"Ross","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.012_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-020-0336-z","article-title":"Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns","volume":"10","author":"Schinke","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.012_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-021-00414-6","article-title":"A\u00a0clinical perspective on plasma cell leukemia; current status and future directions","volume":"11","author":"Tuazon","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.012_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/life12060812","article-title":"Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup","volume":"12","author":"Wiedmeier-Nutor","year":"2022","journal-title":"Life"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.012_bib21","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1182\/blood-2015-06-650242","article-title":"Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?","volume":"126","author":"Chretien","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib22","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.012_bib23","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.012_bib24","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.012_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"issue":"sup1","key":"10.1016\/j.hoc.2023.12.012_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27 Kip1 and an aggressive clinical course in multiple myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Hematology"},{"issue":"7339","key":"10.1016\/j.hoc.2023.12.012_bib27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-018-0160-x","article-title":"Molecular signatures of multiple myeloma progression through single cell RNA-Seq","volume":"9","author":"Jang","year":"2019","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.012_bib29","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.012_bib30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib31","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-021-22804-x","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib32","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41467-022-28266-z","article-title":"Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma","volume":"13","author":"Merz","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.012_bib34","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","article-title":"Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease","volume":"41","author":"Dang","year":"2023","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.012_bib35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: How? When?","volume":"133","author":"Zamagni","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.012_bib36","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.012_bib37","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.012_bib39","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2023.12.012_bib40","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"7218","key":"10.1016\/j.hoc.2023.12.012_bib41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature07485","article-title":"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome","volume":"456","author":"Ley","year":"2008","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.012_bib42","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41375-021-01492-y","article-title":"Cell-free DNA for the detection of emerging treatment failure in relapsed\/refractory multiple myeloma","volume":"36","author":"Waldschmidt","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.012_bib43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/ejh.13541","article-title":"Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA","volume":"106","author":"Deshpande","year":"2021","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.012_bib44","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.hoc.2023.12.012_bib45","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/bloodadvances.2020004131","article-title":"Prognostic impact of posttransplant FDG PET\/CT scan in multiple myeloma","volume":"5","author":"Kaddoura","year":"2021","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.012_bib46","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"Moreau","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.012_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020217","article-title":"The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.012_bib48","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1097\/HS9.0000000000000894","article-title":"The Immune Microenvironment in Multiple Myeloma Progression at a Single-cell Level","volume":"7","author":"Schinke","year":"2023","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.012_bib49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.012_bib50","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/1078-0432.CCR-17-2627","article-title":"The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma","volume":"24","author":"Schinke","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.012_bib51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.a.23693","article-title":"High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action","volume":"95","author":"Adams","year":"2019","journal-title":"Cytometry"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.012_bib53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.012_bib54","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1182\/bloodadvances.2022007217","article-title":"Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level","volume":"6","author":"Schinke","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.012_bib55","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T\u00a0cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib56","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1038\/s41467-023-40584-4","article-title":"Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level","volume":"14","author":"John","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood.2018880930","article-title":"A\u00a0niche-dependent myeloid transcriptome signature defines dormant myeloma cells","volume":"134","author":"Khoo","year":"2019","journal-title":"Blood"},{"issue":"7381","key":"10.1016\/j.hoc.2023.12.012_bib58","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.012_bib59","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.12805","article-title":"The impact of intra-clonal heterogeneity on the treatment of multiple myeloma","volume":"165","author":"Brioli","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.012_bib60","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.012_bib61","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.012_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020256","article-title":"Gain\/Amplification of Chromosome Arm 1q21 in Multiple Myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.012_bib63","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/bloodadvances.2019001275","article-title":"Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma","volume":"4","author":"Mellors","year":"2020","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.012_bib64","first-page":"2919","article-title":"MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma","volume":"128","author":"Qiang","year":"2016","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib65","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1186\/s12885-018-4602-4","article-title":"MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma","volume":"18","author":"Qiang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hoc.2023.12.012_bib66","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023019637","article-title":"IMiD Resistance in Multiple Myeloma: Current Understanding of the Underpinning Biology and Clinical Impact","author":"Bird","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib67","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2023.12.012_bib68","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023019758","article-title":"Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis","author":"Poos","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib69","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat Commun"},{"issue":"23","key":"10.1016\/j.hoc.2023.12.012_bib70","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.V126.23.371.371","article-title":"Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing","volume":"126","author":"Melchor","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib71","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/s41467-020-17459-z","article-title":"Accelerated single cell seeding in relapsed multiple myeloma","volume":"11","author":"Landau","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.012_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020613","article-title":"Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma","volume":"21","author":"Ria","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"37","key":"10.1016\/j.hoc.2023.12.012_bib73","doi-asserted-by":"crossref","first-page":"60698","DOI":"10.18632\/oncotarget.10849","article-title":"Microenvironment drug resistance in multiple myeloma: emerging new players","volume":"7","author":"Di Marzo","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib74","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.V89.1.227","article-title":"Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells","volume":"89","author":"Chauhan","year":"1997","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.012_bib75","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.012_bib76","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.semcancer.2010.04.003","article-title":"Adhesion molecules\u2014The lifelines of multiple myeloma cells","volume":"20","author":"Katz","year":"2010","journal-title":"Semin Cancer Biol"},{"issue":"38","key":"10.1016\/j.hoc.2023.12.012_bib77","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1038\/sj.onc.1203782","article-title":"Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)","volume":"19","author":"Hazlehurst","year":"2000","journal-title":"Oncogene"},{"issue":"23","key":"10.1016\/j.hoc.2023.12.012_bib78","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1182\/blood-2010-06-292243","article-title":"Integrin \u03b27-mediated regulation of multiple myeloma cell adhesion, migration, and invasion","volume":"117","author":"Neri","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.012_bib79","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1182\/blood.2021011670","article-title":"How I approach smoldering multiple myeloma","volume":"140","author":"Vaxman","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2010.11.003","article-title":"Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma","volume":"48","author":"Zingone","year":"2011","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib81","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/hematology.2021000304","article-title":"Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies","volume":"2021","author":"Visram","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.012_bib82","first-page":"2586","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"The Journal of the American Society of Hematology"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.012_bib83","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.012_bib84","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.012_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.012_bib86","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.012_bib87","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.012_bib88","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.012_bib89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-142584","article-title":"Aggressive smoldering curative approach evaluating novel therapies (ASCENT): A phase 2 trial of induction, consolidation and maintenance in subjects with high risk smoldering multiple myeloma (SMM): Initial analysis of safety data","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.012_bib90","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood-2021-148423","article-title":"Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd","volume":"138","author":"Mateos","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.012_bib91","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","article-title":"Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial","volume":"7","author":"Kazandjian","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.012_bib92","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib93","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.012_bib94","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2023.12.012_bib95","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1182\/bloodadvances.2020002838","article-title":"Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87\/NMSG-18 trial","volume":"4","author":"Kuiper","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.hoc.2023.12.012_bib96","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib97","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/leu.2012.160","article-title":"Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?","volume":"27","author":"Usmani","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.012_bib98","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-019-0264-y","article-title":"Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma","volume":"9","author":"Yellapantula","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.012_bib99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fonc.2020.00189","article-title":"Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?","volume":"10","author":"Bolli","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.012_bib100","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/leu.2015.208","article-title":"Inhibiting MEK in MAPK pathway-activated myeloma","volume":"30","author":"Heuck","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.012_bib101","first-page":"8894031","article-title":"Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation","volume":"2020","author":"\u010cepulyt\u0117","year":"2020","journal-title":"Case Rep Hematol"},{"issue":"14","key":"10.1016\/j.hoc.2023.12.012_bib102","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood.2022017789","article-title":"A\u00a0phase 2 clinical trial of combined BRAF\/MEK inhibition for BRAFV600E-mutated multiple myeloma","volume":"141","author":"Giesen","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.012_bib103","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"issue":"100643","key":"10.1016\/j.hoc.2023.12.012_bib104","article-title":"The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma","volume":"41","author":"Paner","year":"2020","journal-title":"Blood Rev"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.012_bib105","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.012_bib106","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2023.12.012_bib107","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.4155\/fmc-2016-0071","article-title":"H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development","volume":"8","author":"Rogawski","year":"2016","journal-title":"Future Med Chem"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib108","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2010-07-298349","article-title":"The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells","volume":"117","author":"Martinez-Garcia","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.012_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004566","article-title":"Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation","volume":"10","author":"Popovic","year":"2014","journal-title":"PLoS Genet"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.012_bib110","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.3324\/haematol.2020.266858","article-title":"Novel immunotherapies in multiple myeloma - chances and challenges","volume":"106","author":"Rasche","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.012_bib111","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T\u00a0cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.012_bib112","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T\u00a0cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.012_bib113","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/157339471002141124121404","article-title":"Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma","volume":"10","author":"Bianchi","year":"2014","journal-title":"Curr Cancer Ther Rev"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882300179X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882300179X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:19:57Z","timestamp":1760591997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985882300179X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":113,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S088985882300179X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.012","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Clonal Heterogeneity in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}